AI Article Synopsis
- - Patients aged 80 and older represent a significant portion of chronic lymphocytic leukemia (CLL) cases but are often excluded from clinical trials, making it hard to assess treatment efficacy in this age group.
- - An analysis of six trials involving targeted treatments such as venetoclax and ibrutinib showed a promising 73% overall response rate among the 33 older patients studied, despite many having serious health issues.
- - The median progression-free survival for these patients was impressive at 49.2 months, indicating that targeted therapies are both feasible and effective, suggesting the need for more tailored studies for older CLL patients.
Article Abstract
Patients aged 80 years and older make up a fifth of patients with CLL but are underrepresented in clinical trials. We analyzed the outcomes of these patients treated with targeted agents in the front-line setting in six trials of the German CLL Study Group. Targeted agents included venetoclax, ibrutinib, and idelalisib, mainly used in combination with anti-CD20 antibodies. Among 716 patients, 33 matched the selection criteria (5%). Of those, the majority had relevant comorbidity, organ dysfunctions, and/or high-/very high-risk disease. The overall response rate was 73%. The median progression-free survival was 49.2 months compared with those not reached in younger patients. There were 11 documented deaths of which two were deemed related to therapy. Additional results including 40 patients treated with BTK-inhibitors from the GCLLSG registry suggest that treatment with targeted agents is feasible and effective. Dedicated studies are warranted for this particular subgroup of patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2022.2123223 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!